Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals

References

• Kumari G, Singh RK. Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr Pharm Des. 2013;19(10):1767–1783. PubMed PMID: WOS:000316455200002.
   PubMed Web of Science ®Google Scholar
• Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;14(1):47–58. doi:10.1089/108729100318127. PubMed PMID: WOS:000085014300007.
   PubMed Web of Science ®Google Scholar
• Garcia F, Plana M, Climent N, Leon A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection The way ahead. Hum Vaccin Immunother. 2013;9(11):2445–2452. doi:10.4161/hv.25876. PubMed PMID: WOS:000330382300029.
   PubMed Web of Science ®Google Scholar
• Garcia F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine. 2011;29(38):6454–6463. doi:10.1016/j.vaccine.2011.07.043. PubMed PMID: WOS:000295148800009.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YT, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811. doi:10.1146/annurev.immunol.18.1.767. PubMed PMID: WOS:000087236500026.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837. doi:10.1126/science.284.5421.1835. PubMed PMID: WOS:000080809000050.
   PubMed Web of Science ®Google Scholar
• Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis. 2003;187(1):26–37. doi:10.1086/345957. PubMed PMID: WOS:000179809900005.
   PubMed Web of Science ®Google Scholar
• Coelho AVC, de Moura RR, Kamada AJ, da Silva RC, Guimaraes RL, Brandao LAC, de Alencar LCA, Crovella S. Dendritic cell-based immunotherapies to fight HIV: how far from a success story? A systematic review and meta-analysis. Int J Mol Sci. 2016;17(12):1985. doi:10.3390/ijms17121985. PubMed PMID: WOS:000392280500029.
   Web of Science ®Google Scholar
• Shang N, Figini M, Shangguan J, Wang B, Sun C, Pan L, Ma QH, Zhang ZL. Dendritic cells based immunotherapy. Am J Cancer Res. 2017;7(10):2091–2102. PubMed PMID: WOS:000414291400010.
   PubMed Web of Science ®Google Scholar
• Constantino J, Gomes C, Falcao A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65(4):798–810. doi:10.1007/s12026-017-8931-1. PubMed PMID: WOS:000407325000004.
   PubMed Web of Science ®Google Scholar
• Leal L, Lucero C, Gatell JM, Gallart T, Plana M, Garcia F. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017;16(6):587–600. doi:10.1080/14760584.2017.1322513. PubMed PMID: WOS:000401437800007.
   PubMed Web of Science ®Google Scholar
• Della Bella S, Nicola S, Riva A, Biasin M, Clerici M, Villa ML. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J Leukoc Biol. 2004;75(1):106–116. doi:10.1189/jlb.0403154. PubMed PMID: WOS:000188741200014.
   PubMed Web of Science ®Google Scholar
• Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64(3):358–367. PubMed PMID: WOS:000075745100011.
   PubMed Web of Science ®Google Scholar
• Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, Parlato S, Belardelli F. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med. 2003;198(2):361–367. doi:10.1081/jem.20021924. PubMed PMID: WOS:000184368200018.
   PubMed Web of Science ®Google Scholar
• Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol. 2006;36(8):2046–2060. doi:10.1002/eji.200535579. PubMed PMID: WOS:000239855900006.
   PubMed Web of Science ®Google Scholar
• Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, Ramoni C, Filesi I, Biocca S, Gabriele L, et al. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood. 2010;115(8):1554–1563. doi:10.1182/blood-2009-07-234468. PubMed PMID: WOS:000274974200014.
   PubMed Web of Science ®Google Scholar
• Korthals M, Safaian N, Kronenwett R, Maihofer D, Schott M, Papewalis C, Blanco ED, Winter M, Czibere A, Haas R, et al. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med. 2007;5:46. doi:10.1186/1479-5876-5-46. PubMed PMID: WOS:000250873000001.
   PubMed Web of Science ®Google Scholar
• Farkas A, Kemeny L. Interferon-alpha in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br J Dermatol. 2011;165(2):247–254. doi:10.1111/j.1365-2133.2011.10301.x. PubMed PMID: WOS:000292926900006.
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64(17):5934–5937. doi:10.1158/0008-5472.can-04-1261. PubMed PMID: WOS:000223603200005.
   PubMed Web of Science ®Google Scholar
• Hansen M, Hjorto GM, Donia M, Met O, Larsen NB, Andersen MH, Straten PT, Svane IM. Comparison of clinical grade type I polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine. 2013;31(4):639–646. doi:10.1016/j.vaccine.2012.11.053. PubMed PMID: WOS:000314625900010.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8(+) T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant Glioma. J Clin Oncol. 2011;29(3):330–336. doi:10.1200/jco.2010.30.7744. PubMed PMID: WOS:000286319000024.
   PubMed Web of Science ®Google Scholar
• Rozera C, Cappellini GA, D’Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Arico E, Casorelli I, Sestili P, et al. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med. 2015;13. doi:10.1186/s12967-015-0473-5. PubMed PMID: WOS:000369795900001.
   PubMed Web of Science ®Google Scholar
• Rizza P, Moretti F, Capone I, Belardelli F. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 2015;26(2):195–201. doi:10.1016/j.cytogfr.2014.10.002. PubMed PMID: WOS:000353730700012.
   PubMed Web of Science ®Google Scholar
• Hwang EC, Il Jung S, Lee HJ, Lee JJ, Kwon DD. Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells. Int Braz J Urol. 2017;43(4):615–627. doi:10.1590/s1677-5538.ibju.2016.0274. PubMed PMID: WOS:000407352000007.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tran TAT, Lee HJ, Jung SI, Lee JJ, Jang WY, Moon KS, Kim IY, Jung S, Jung TY. Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99. Oncotarget. 2016;7(31):50535–50547. doi:10.18632/oncotarget.10495. PubMed PMID: WOS:000385422000130.
   PubMedGoogle Scholar
• Levy Y, Thiebaut R, Montes M, Lacabaratz C, Sloan L, King B, Perusat S, Harrod C, Cobb A, Roberts LK, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol. 2014;44(9):2802–2810. doi:10.1002/eji.201344433. PubMed PMID: WOS:000342818900026.
   PubMed Web of Science ®Google Scholar
• Smith KN, Mailliard RB, Piazza PA, Fischer W, Korber BT, Fecek RJ, Ratner D, Gupta P, Mullins JI, Rinaldo CR. Effective cytotoxic T lymphocyte targeting of persistent HIV-1 during antiretroviral therapy requires priming of naive CD8(+) T cells (vol 7, e00473, 2016). MBio. 2016;7(4). doi:10.1128/mBio.01012-16. PubMed PMID: WOS:000383440500049.
   Web of Science ®Google Scholar
• Macatangay BJC, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, et al. Therapeutic vaccination with dendritic cells loaded with autologous HIV type 1-Infected apoptotic cells. J Infect Dis. 2016;213(9):1400–1409. doi:10.1093/infdis/jiv582. PubMed PMID: WOS:000376295800007.
   PubMed Web of Science ®Google Scholar
• Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF. Prostaglandin E-2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood. 2009;113(11):2451–2460. doi:10.1182/blood-2008-05-157123. PubMed PMID: WOS:000264110600013.
   PubMed Web of Science ®Google Scholar
• Rubio MT, Means TK, Chakraverty R, Shaffer J, Fudaba Y, Chittenden M, Luster AD, Sykes M. Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E-2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE(2) in chemokine and cytokine expression by MoDCs. Int Immunol. 2005;17(12):1561–1572. doi:10.1093/intimm/dxh335. PubMed PMID: WOS:000233669100005.
   PubMed Web of Science ®Google Scholar
• Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9(7):861–866. doi:10.1038/nm0703-861. PubMed PMID: WOS:000183979300025.
   PubMed Web of Science ®Google Scholar
• Walker B, McMichael A. The T-Cell response to HIV. Cold Spring Harb Perspect Med. 2012;2(11):a007054–a007054. doi:10.1101/cshperspect.a007054. PubMed PMID: WOS:000314282300014.
   PubMed Web of Science ®Google Scholar
• Porichis F, Kaufmann DE. HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS. 2011;6(3):174–180. doi:10.1097/COH.0b013e3283454058. PubMed PMID: WOS:000295513000006.
   PubMed Web of Science ®Google Scholar
• Kodama A, Tanaka R, Saito M, Ansari AA, Tanaka Y. A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice. Front Microbiol. 2013;4. doi:10.3389/fmicb.2013.00292. PubMed PMID: WOS:000331444100001.
   PubMed Web of Science ®Google Scholar
• Xu SW, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8(+) T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003;171(5):2251–2261. doi:10.4049/jimmunol.171.5.2251. PubMed PMID: WOS:000184970900010.
   PubMed Web of Science ®Google Scholar
• Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A. Mature dendritic cells derived from human monocytes within 48 hours: A novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170(8):4069–4076. doi:10.4049/jimmunol.170.8.4069. PubMed PMID: WOS:000182171100017.
   PubMed Web of Science ®Google Scholar
• Czerniecki BJ, Koski GK, Koldovsky U, Xu SW, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67(4):1842–1852. doi:10.1158/0008-5472.can-06-4038. PubMed PMID: WOS:000244289200053.
   PubMed Web of Science ®Google Scholar
• Tyrinova TV, Leplina OY, Tikhonova MA, Mishinov SV, Stupak VV, Ostanin AA, Chernykh ER. CCL19/CCL21-Dependent chemotaxis of dendritic cells in healthy individuals and patients with brain tumors. Bull Exp Biol Med. 2015;158(6):785–788. doi:10.1007/s10517-015-2862-4. PubMed PMID: WOS:000354066800021.
   PubMed Web of Science ®Google Scholar
• Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood. 2012;119(6):1407–1417. doi:10.1182/blood-2011-06-363564. PubMed PMID: WOS:000300420900017.
   PubMed Web of Science ®Google Scholar
• Leplina OY, Tyrinova TV, Tikhonova MA, Ostanin AA, Chernykh ER. Interferon alpha induces generation of semi-mature dendritic cells with high pro-inflammatory and cytotoxic potential. Cytokine. 2015;71(1):1–7. doi:10.1016/j.cyto.2014.07.258. PubMed PMID: WOS:000347584600001.
   PubMed Web of Science ®Google Scholar
• da Silva LT, Pontillo A, da Silva WC, de Almeida A, Duarte AJD, Oshiro TM. Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine? Immunotherapy. 2013;5(12):1305–1311. doi:10.2217/imt.13.136. PubMed PMID: WOS:000327426800012.
   PubMed Web of Science ®Google Scholar
• Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998;72(10):7992–8001. PubMed PMID: WOS:000075864100033.
   PubMed Web of Science ®Google Scholar